Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-25 @ 10:01 PM
Study NCT ID:
NCT01423058
Status:
COMPLETED
Last Update Posted:
2019-02-04
First Post:
2011-07-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Sponsor:
Sierra Oncology LLC - a GSK company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-08
Start Date Type:
None
Primary Completion Date:
2014-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-06
Completion Date Type:
ACTUAL
First Submit Date:
2011-07-07
First Submit QC Date:
None
Study First Post Date:
2011-08-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2015-01-28
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2019-01-31
Last Update Post Date:
2019-02-04
Last Update Post Date Type:
ACTUAL